A Phase 1, Open Label, Single Dose, Parallel Group Study To Evaluate The Plasma Pharmacokinetics Of Glasdegib (Pf-04449913) In Healthy Subjects With Normal Hepatic Function And In Subjects With Impaired Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 06 May 2019
Price : $35 *
At a glance
- Drugs Glasdegib (Primary)
- Indications Acute myeloid leukaemia; Cancer; Chronic myelomonocytic leukaemia; Glioblastoma; Graft-versus-host disease; Haematological malignancies; Myelodysplastic syndromes; Myelofibrosis; Solid tumours
- Focus Pharmacokinetics
- Sponsors Pfizer
- 01 May 2019 Status changed from recruiting to completed.
- 22 Mar 2019 Planned End Date changed from 13 May 2019 to 11 Apr 2019.
- 22 Mar 2019 Planned primary completion date changed from 13 May 2019 to 11 Apr 2019.